Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Ashwin S. Kumar"'
Autor:
Igor L. Gomes-Santos, Ashwin S. Kumar, Franziska Hausmann, Max N. Meyer, Sarah Z. Shiferaw, Zohreh Amoozgar, Rakesh K. Jain, Dai Fukumura
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionExercise is recommended as an adjunct therapy in cancer, but its effectiveness varies. Our hypothesis is that the benefit depends on the exercise intensity.MethodsWe subjected mice to low intensity (Li), moderate intensity (Mi) or high in
Externí odkaz:
https://doaj.org/article/3286f5901d15482c9df4530aa3a8ab72
Autor:
Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-6 (2021)
Abstract A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings
Externí odkaz:
https://doaj.org/article/2d357221a247457589d886c5e06e1e3d
Autor:
Yves Boucher, Jessica M. Posada, Sonu Subudhi, Ashwin S. Kumar, Spencer R. Rosario, Liqun Gu, Heena Kumra, Mari Mino-Kenudson, Nilesh P. Talele, Dan G. Duda, Dai Fukumura, Jennifer Y. Wo, Jeffrey W. Clark, David P. Ryan, Carlos Fernandez-Del Castillo, Theodore S. Hong, Mikael J. Pittet, Rakesh K. Jain
Publikováno v:
Clinical Cancer Research. 29:1605-1619
Purpose: Adding losartan (LOS) to FOLFIRINOX (FFX) chemotherapy followed by chemoradiation (CRT) resulted in 61% R0 surgical resection in our phase II trial in patients with locally advanced pancreatic cancer (LAPC). Here we identify potential mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a172e9457377d283c4f90bae25db37f3
https://doi.org/10.1158/1078-0432.ccr-22-1630
https://doi.org/10.1158/1078-0432.ccr-22-1630
Autor:
Rakesh K. Jain, Mikael J. Pittet, Theodore S. Hong, Carlos Fernandez-Del Castillo, David P. Ryan, Jeffrey W. Clark, Jennifer Y. Wo, Dai Fukumura, Dan G. Duda, Nilesh P. Talele, Mari Mino-Kenudson, Heena Kumra, Liqun Gu, Spencer R. Rosario, Ashwin S. Kumar, Sonu Subudhi, Jessica M. Posada, Yves Boucher
Venn plots and selected GSEA pathways.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32aa766e188dfb7efdbae9354c85712c
https://doi.org/10.1158/1078-0432.22633054.v1
https://doi.org/10.1158/1078-0432.22633054.v1
Autor:
Rakesh K. Jain, Mikael J. Pittet, Theodore S. Hong, Carlos Fernandez-Del Castillo, David P. Ryan, Jeffrey W. Clark, Jennifer Y. Wo, Dai Fukumura, Dan G. Duda, Nilesh P. Talele, Mari Mino-Kenudson, Heena Kumra, Liqun Gu, Spencer R. Rosario, Ashwin S. Kumar, Sonu Subudhi, Jessica M. Posada, Yves Boucher
Longitudinal analysis of circulating biomarkers in the plasma of treated patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e1f148ae1cbc18e85df3cde2c1dc852
https://doi.org/10.1158/1078-0432.22633018.v1
https://doi.org/10.1158/1078-0432.22633018.v1
Autor:
Dai Fukumura, Rakesh K. Jain, Kosuke Kawaguchi, Hannah Curtis, Nilesh P. Talele, Kangsan Roh, William W. Ho, Ashwin S. Kumar, Zohreh Amoozgar, Igor L. Gomes-Santos
Supplemental Figures 1-11 and Supplementary table.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fe9b71d2a808127b9eb736a9b9cd3e6
https://doi.org/10.1158/2326-6066.22543114
https://doi.org/10.1158/2326-6066.22543114
Autor:
Dai Fukumura, Rakesh K. Jain, Kosuke Kawaguchi, Hannah Curtis, Nilesh P. Talele, Kangsan Roh, William W. Ho, Ashwin S. Kumar, Zohreh Amoozgar, Igor L. Gomes-Santos
The mechanisms behind the antitumor effects of exercise training (ExTr) are not fully understood. Using mouse models of established breast cancer, we examined here the causal role of CD8+ T cells in the benefit acquired from ExTr in tumor control, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36531fc968c1470cf6bbe5d625170b52
https://doi.org/10.1158/2326-6066.c.6550141
https://doi.org/10.1158/2326-6066.c.6550141
Autor:
Rakesh K. Jain, Mikael J. Pittet, Theodore S. Hong, Carlos Fernandez-Del Castillo, David P. Ryan, Jeffrey W. Clark, Jennifer Y. Wo, Dai Fukumura, Dan G. Duda, Nilesh P. Talele, Mari Mino-Kenudson, Heena Kumra, Liqun Gu, Spencer R. Rosario, Ashwin S. Kumar, Sonu Subudhi, Jessica M. Posada, Yves Boucher
Purpose:Adding losartan (LOS) to FOLFIRINOX (FFX) chemotherapy followed by chemoradiation (CRT) resulted in 61% R0 surgical resection in our phase II trial in patients with locally advanced pancreatic cancer (LAPC). Here we identify potential mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13001e66444ae716730ec0d78389351c
https://doi.org/10.1158/1078-0432.c.6533155.v1
https://doi.org/10.1158/1078-0432.c.6533155.v1
Autor:
Scott J. Rodig, Kathleen L. Pfaff, Yves Boucher, Dan G. Duda, Evisa Gjini, Mikel Lipschitz, Rakesh K. Jain, Ana Lako, Ashwin S. Kumar, F. Stephen Hodi, Jessica M. Posada
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-6 (2021)
NPJ Precision Oncology
NPJ Precision Oncology
A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b45e9b14cc2492ef71c80d2a6b2b0f6
https://doaj.org/article/2d357221a247457589d886c5e06e1e3d
https://doaj.org/article/2d357221a247457589d886c5e06e1e3d
Autor:
Meenal Datta, Sampurna Chatterjee, Elizabeth M. Perez, Simon Gritsch, Sylvie Roberge, Mark Duquette, Ivy X. Chen, Kamila Naxerova, Ashwin S. Kumar, Mitrajit Ghosh, Kyrre E. Emblem, Mei R. Ng, William W. Ho, Pragya Kumar, Shanmugarajan Krishnan, Xinyue Dong, Maria C. Speranza, Martha R. Neagu, David A. Reardon, Arlene H. Sharpe, Gordon J. Freeman, Mario L. Suvà, Lei Xu, Rakesh K. Jain
Immune checkpoint blockers (ICBs) have failed in all Phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, and T cell blockin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6474488349a3ee36820acad414ac747
https://doi.org/10.1101/2022.06.28.497997
https://doi.org/10.1101/2022.06.28.497997